BR0307337A - Tratamento de disfunção sexual masculina - Google Patents

Tratamento de disfunção sexual masculina

Info

Publication number
BR0307337A
BR0307337A BR0307337-8A BR0307337A BR0307337A BR 0307337 A BR0307337 A BR 0307337A BR 0307337 A BR0307337 A BR 0307337A BR 0307337 A BR0307337 A BR 0307337A
Authority
BR
Brazil
Prior art keywords
treatment
sexual dysfunction
male sexual
male
oxytocin antagonist
Prior art date
Application number
BR0307337-8A
Other languages
English (en)
Inventor
Alasdair Mark Naylor
Rachel Jane Russell
Stephen Derek Albert Street
Kim-Wah Tang
Pieter Hadewijn Van Der Graaf
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0307337A publication Critical patent/BR0307337A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"TRATAMENTO DE DISFUNçãO SEXUAL MASCULINA". A presente invenção refere-se a uma composição compreendendo um antagonista seletivo de oxitocina para usar no tratamento e/ou prevenção de um distúrbio ejaculatório masculino; este antagonista seletivo da oxitocina sendo opcionalmente misturado com um veículo, diluente ou excipiente farmaceuticamente aceitável.
BR0307337-8A 2002-01-31 2003-01-20 Tratamento de disfunção sexual masculina BR0307337A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202282.0A GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction
PCT/IB2003/000140 WO2003064402A1 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
BR0307337A true BR0307337A (pt) 2004-12-07

Family

ID=9930155

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307337-8A BR0307337A (pt) 2002-01-31 2003-01-20 Tratamento de disfunção sexual masculina

Country Status (16)

Country Link
EP (1) EP1470115A1 (pt)
JP (3) JP2005525321A (pt)
KR (2) KR100829262B1 (pt)
CN (1) CN100500658C (pt)
AU (1) AU2003201471B2 (pt)
BR (1) BR0307337A (pt)
CA (1) CA2474590A1 (pt)
GB (1) GB0202282D0 (pt)
HK (1) HK1073109A1 (pt)
IL (2) IL162822A0 (pt)
MX (1) MXPA04007434A (pt)
NZ (1) NZ546408A (pt)
PL (1) PL371415A1 (pt)
TW (1) TW200302732A (pt)
WO (1) WO2003064402A1 (pt)
ZA (1) ZA200405208B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
AU690534B2 (en) * 1992-12-23 1998-04-30 Merck & Co., Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
JP2703864B2 (ja) * 1993-03-12 1998-01-26 メルク エンド カムパニー インコーポレーテッド ピペリジニルショウノウスルホニルオキシトシンアンタゴニスト誘導体の製造方法
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
US20020028799A1 (en) * 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
GB0202282D0 (en) 2002-03-20
WO2003064402A1 (en) 2003-08-07
IL162822A0 (en) 2005-11-20
PL371415A1 (en) 2005-06-13
JP2013151511A (ja) 2013-08-08
AU2003201471B2 (en) 2009-03-26
KR100829262B1 (ko) 2008-05-13
MXPA04007434A (es) 2004-10-11
IL162822A (en) 2010-11-30
CA2474590A1 (en) 2003-08-07
EP1470115A1 (en) 2004-10-27
JP2005525321A (ja) 2005-08-25
ZA200405208B (en) 2005-08-31
CN100500658C (zh) 2009-06-17
KR20080011232A (ko) 2008-01-31
NZ546408A (en) 2007-10-26
CN1625553A (zh) 2005-06-08
TW200302732A (en) 2003-08-16
KR20040079958A (ko) 2004-09-16
JP2010209075A (ja) 2010-09-24
HK1073109A1 (en) 2005-09-23

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
MXPA05013142A (es) Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
CY1114445T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για χρηση στη θεραπευτικη αγωγη ή προληψη αυτοανοσων ασθενειων
IL169439A0 (en) Fluoroalkoxy-substituted 1,3 - dihydro-isoindolyl compounds and their pharmaceutical uses
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
TNSN07240A1 (en) Compounds for flaviviridae treatment
WO2004005324A3 (en) Peptide composition for treatment of sexual dysfunction
TW200509896A (en) Analeptic and drug combinations
MY137620A (en) Therapeutic treatment
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
MX2007004461A (es) Composiciones farmaceuticas a base de antagonistas de nk2 para uso pediatrico.
BR0307337A (pt) Tratamento de disfunção sexual masculina
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
GEP20115184B (en) Pharmacokinetically improved compounds
BRPI0414423A (pt) inibidores de pace4, suas composições farmacêuticas e respectivos usos
PT1355650E (pt) Combinacao de ingredientes activos contendo alfuzosina e apomorfina
GEP20043347B (en) Use of Pyrazolopyrimidinones for Treatment of Impotence
CL2004001071A1 (es) Composicion farmaceutica que comprende modafinilo, un farmaco antineoplasico y un vehiculo farmaceuticamente aceptable.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.